Form 4: Director Constantine Mihas Receives Maravai Equity Grant
Director Equity Grant Disclosure
Maravai LifeSciences director Constantine Mihas was granted 46,293 restricted stock units as part of the company's 2020 Omnibus Incentive Plan.
Summary
- Director Constantine Mihas received an award of 46,293 restricted stock units (RSUs) on May 26, 2026.
- The RSUs vest in full on the earlier of one year from the grant date or the 2027 annual meeting of stockholders.
- Following this transaction, the reporting person beneficially owns 184,348 shares of Class A Common Stock.
- The reporting person holds these securities for the benefit of a GTCR-affiliated entity and disclaims personal pecuniary interest.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- None identified; this is a standard compensatory equity grant for a board member.
Risks
- None identified; this is a routine disclosure of director equity compensation.
Future Outlook
The RSUs are scheduled to vest in full by the 2027 annual meeting of stockholders.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to align director incentives with company performance in the life sciences sector.
Comparison to Industry Standards
- The grant follows standard industry practices for director compensation in mid-cap life sciences companies.
- The vesting schedule is consistent with typical one-year cliff vesting cycles for non-employee directors.
Related Party Transactions
- The reporting person holds securities for the benefit of a GTCR-affiliated entity.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard equity incentive grant.
Next Steps
- Vesting of the 46,293 RSUs on or before the 2027 annual meeting of stockholders.
Key Dates
| Date | Description |
|---|---|
| 05/26/2026 | Date of the RSU grant transaction. |
| 05/28/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Maravai LifeSciences, MRVI, Form 4, Insider Trading, Equity Compensation, GTCR
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.